KI
PTGX icon

Keystone Investors’s Protagonist Therapeutics PTGX Stock Holding History

Keystone Investors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.3M Buy
+26,390
New +$2.16M 0.21% 49

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Keystone Investors's PTGX Position: Q4 2025 in Review

Keystone Investors opened a new position in Protagonist Therapeutics (PTGX) in Q4 2025: 26,390 shares worth $2.3M. The stake represents 0.21% of the portfolio and ranks #49 among its holdings.

314 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • Keystone Investors held 26,390 shares of Protagonist Therapeutics worth $2.3M as of Q4 2025.
  • Protagonist Therapeutics was a new Keystone Investors position in Q4 2025.
  • Protagonist Therapeutics made up 0.21% of Keystone Investors's portfolio in Q4 2025, its #49 holding.
  • 314 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Keystone Investors's 13F filing for Q4 2025, filed 13 Feb 2026.